Product Program year 2025 Source: CMS Open Payments

Gammagard Liquid

Biological Immunology

NDC 0944-2700-02

Open in the dashboard

General payments

$316,938

456 payments

Research payments

$0

0 payments

Through program year 2025, $316,938 in general payments and $0 in research payments were reported against Gammagard Liquid (Immunology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2025 General $78,520 29
2024 General $8,000 11
2023 General $25,962 108
2022 General $73,740 107
2021 General $52,280 64
2020 General $25,528 37
2019 General $52,908 100

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $264,030 356 payments
  2. Shire North American Group Inc $52,908 100 payments
Top recipients General payments · program year 2025
  1. Jamil Azzi Nephrology · Boston, MA $25,486 32% · 9 payments
  2. Flavio Vincenti Internal Medicine · San Francisco, CA $25,381 32% · 7 payments
  3. Enver Akalin Nephrology · Bronx, NY $22,983 29% · 8 payments
  4. Jeffery Allen Neurology · Minneapolis, MN $2,940 4% · 1 payment
  5. Marc Riedl Allergy & Immunology · San Diego, CA $536 <1% · 1 payment

The top 5 of 8 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Nephrology Internal Medicine $48,590 62% · 3 practitioners
  2. Internal Medicine $25,381 32% · 1 practitioner
  3. Neurology Psychiatry & Neurology $2,940 4% · 1 practitioner
  4. Allergy & Immunology Internal Medicine $536 <1% · 1 practitioner
  5. Pediatric Allergy/Immunology Pediatrics $536 <1% · 1 practitioner

The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $25,917 33% · 2 recipients
  2. Massachusetts $25,486 32% · 1 recipient
  3. New York $24,055 31% · 3 recipients
  4. Minnesota $2,940 4% · 1 recipient
  5. Texas $122 <1% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

48,481

Prescriptions dispensed, refills included

Drug cost

$499,734,387

Paid at the pharmacy, in all

Prescribers

1,719

With 11 or more claims of it

Medicare Part D drugs matched to GAMMAGARD LIQUID, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Same name 1,719 48,481 $499,734,387

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Ann Little Neurology MI 333 $3,572,529 No profile
Douglas Davies Neurology CA 306 $1,483,149 None on record
Robert Wilson Neurosurgery FL 305 $3,498,705 None on record
Shalini Mahajan Neurology CA 253 $2,369,441 None on record
Payam Soltanzadeh Neurology CA 250 $2,162,833 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to GAMMAGARD LIQUID
Billing code Providers Services Paid by Medicare
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 593 2,848,101 $101,026,280

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

456 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record